Video

Choosing the Appropriate CAR T-Cell Therapy in Patients with R/R DLBCL

Author(s):

Manali Kamdar, MD,Matthew A. Lunning, DO, FACP

Dr Lunning, DO, FACP, shares his impressions on the toxicity profile of axi-cel and liso-cel, and how he approaches treatment decision making for patients with relapsed-refractory (R/R) large B-cell lymphoma (LBCL).

Related Videos
Minoo Battiwalla, MD, MS
David C. Fisher, MD
Alex Herrera, MD
Grzegorz S. Nowakowski, MD
Francisco Hernandez-Ilizaliturri, MD, professor, oncology, Department of Medicine—Lymphoma; director, Lymphoma Research, head, Lymphoma Translational Research Lab; associate professor, Department of Immunology, Roswell Park Comprehensive Cancer Center; clinical professor, Department of Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo
Amitkumar Mehta, MD
Grzegorz S. Nowakowski, MD
Jasmin M. Zain, MD
Grzegorz S. Nowakowski, MD
Grzegorz S. Nowakowski, MD
Related Content
Syed Abbas Ali, MBBS
November 22nd 2024

Bispecific Antibodies and CAR T-Cell Therapies Continue to Reshape Myeloma Treatment Landscape

Matthew Lunning, DO, FACP
December 21st 2023

Lunning and Mehta-Shah Unpack Treatment Needs and Future Directions in PTCL

Chad Williams, PhD
November 11th 2024

Early Serum IL-2 Levels Are Associated With CAR T-Cell Expansion Post–CAR T-Cell Therapy

Matthew Lunning, DO, FACP
October 30th 2023

Lunning and Nastoupil Highlight Treatment Considerations and Ongoing Research in Follicular Lymphoma

FDA
November 8th 2024

FDA Approves Obecabtagene Autoleucel for R/R B-Cell Precursor Acute Lymphoblastic Leukemia

Michel Delforge, MD, PhD
November 1st 2024

Indirect Comparison Shows Superiority of Cilta-Cel vs SOC Regimens in Lenalidomide-Refractory Myeloma